Estimated Testing, Tracing, and Vaccination Targets for Containment of the US Mpox Outbreak
- 3 January 2023
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (1) , e2250984
Abstract
As of November 2022, there have been more than 28 000 confirmed US mpox cases, predominantly among men who have sex with men (MSM).1 Reducing transmission of mpox virus (hMPXV) is crucial to protect the health of MSM and reduce the risk of transmission in the general population. While testing, contact tracing, and vaccination can slow the spread of hMPXV, target levels of these measures have not been established. We aimed to estimate the levels of community testing, contact tracing, and vaccination required to reduce the effective reproduction number (Rt) of hMPXV to less than 1 for high-risk MSM (HR-MSM).Keywords
This publication has 3 references indexed in Scilit:
- Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United StatesAnnals of Internal Medicine, 2022
- Modeling Contact Tracing Strategies for COVID-19 in the Context of Relaxed Physical Distancing MeasuresJAMA Network Open, 2020
- The Transmission Potential of Monkeypox Virus in Human PopulationsInternational Journal of Epidemiology, 1988